Related references
Note: Only part of the references are listed.Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect?
Vasilios G. Athyros et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy Implications for Risk Assessment, Prevention and Treatment
Yiannis S. Chatzizisis et al.
DRUG SAFETY (2010)
Update in Vitamin D
John S. Adams et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Atorvastatin Causes Insulin Resistance and Increases Ambient Glycemia in Hypercholesterolemic Patients
Kwang Kon Koh et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
Naveed Sattar et al.
LANCET (2010)
Does Simvastatin Cause More Myotoxicity Compared with Other Statins?
James M. Backes et al.
ANNALS OF PHARMACOTHERAPY (2009)
Effects of Vitamin D Supplementation in Atorvastatin-Treated Patients: A New Drug Interaction With an Unexpected Consequence
J. B. Schwartz
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Pleiotropic Effects of Statins - Clinical Evidence
Vasilios G. Athyros et al.
CURRENT PHARMACEUTICAL DESIGN (2009)
The SLCO1B1*5 Genetic Variant Is Associated With Statin-Induced Side Effects
Deepak Voora et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients
Waqas Ahmed et al.
TRANSLATIONAL RESEARCH (2009)
High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients - A Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis
Amir Lotfi et al.
AMERICAN HEART JOURNAL (2008)
Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease
James Shepherd et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects
Nagy A. Farid et al.
PHARMACOTHERAPY (2008)
The safety of statins in clinical practice
Jane Armitage
LANCET (2007)
Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study)
John C. LaRosa et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease
Nanette K. Wenger et al.
ANNALS OF INTERNAL MEDICINE (2007)
Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)
James M. McKenney et al.
ATHEROSCLEROSIS (2007)
Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system)
Alawi A. Alsheikh-Ali et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Atorvastatin - A safety and tolerability profile
Marcello Arca
DRUGS (2007)
Risk factors for statin-associated rhabdomyolysis
Stephanie Schech et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2007)
Statins and renal function. Is the compound and dose making a difference?
Vasilios G. Athyros et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2007)
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
Pertti J. Neuvonen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Analysis of efficacy and safety in patients aged 65-75 years at randomization - Collaborative Atorvastatin Diabetes Study (CARDS)
H. Andrew W. Neil et al.
DIABETES CARE (2006)
Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN) - Response to Knopp
Irene F. Gazi et al.
DIABETES CARE (2006)
Efficacy and safe of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes - The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN)
Robert H. Knopp et al.
DIABETES CARE (2006)
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study
Vasilios G. Athyros et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Statin safety: A systematic review
M Law et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Comparative safety of Atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients
C Newman et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Statin-induced myopathy: The two faces of Janus
Rohit Arora et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2006)
Statins and myotoxicity: a therapeutic limitation
Atul Tiwari et al.
EXPERT OPINION ON DRUG SAFETY (2006)
Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients -: The PRIMO study
E Bruckert et al.
CARDIOVASCULAR DRUGS AND THERAPY (2005)
High-dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction - The IDEAL study: A randomized controlled trial
TR Pedersen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
Safety of high-dose atorvastatin therapy
DD Waters
AMERICAN JOURNAL OF CARDIOLOGY (2005)
Targeting vascular risk in patients with metabolic syndrome but without diabetes
VG Athyros et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2005)
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
C Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The safety of rosuvastatin as used in common clinical practice - A postmarketing analysis
AA Alsheikh-Ali et al.
CIRCULATION (2005)
Intensive lipid lowering with atorvastatin in patients with stable coronary disease
JC LaRosa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Atorvastatin - A review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus
KF Croom et al.
DRUGS (2005)
Intensive versus moderate lipid lowering with statins after acute coronary syndromes
CP Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes
JV Mitsios et al.
CIRCULATION (2004)
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
HM Colhoun et al.
LANCET (2004)
Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits
G Anfossi et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2004)
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
DJ Graham et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study
VG Athyros et al.
JOURNAL OF CLINICAL PATHOLOGY (2004)
Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy
JT Chang et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2004)
Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors
TA Jacobson
AMERICAN JOURNAL OF CARDIOLOGY (2004)
Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus - A subgroup analysis of the GREek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study
VG Athyros et al.
ANGIOLOGY (2003)
Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients
CB Newman et al.
AMERICAN JOURNAL OF CARDIOLOGY (2003)
Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis
MR Law et al.
BRITISH MEDICAL JOURNAL (2003)
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):: a multicentre randomised controlled trial
PS Sever et al.
LANCET (2003)
Etiology and frequency of rhabdomyolysis
C Black et al.
PHARMACOTHERAPY (2002)
Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia
VG Athyros et al.
DIABETES CARE (2002)
The liver and lovastatin
KG Tolman
AMERICAN JOURNAL OF CARDIOLOGY (2002)
Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors
D Williams et al.
CLINICAL PHARMACOKINETICS (2002)
Effects of HMG-CoA reductase inhibitors on skeletal muscle - Are all statins the same?
M Evans et al.
DRUG SAFETY (2002)
Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention - The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study
VG Athyros et al.
CURRENT MEDICAL RESEARCH AND OPINION (2002)
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes - The MIRACL study: A randomized controlled trial
GG Schwartz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Share Paper
